Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David N Louis

Showing results (91-100 of 218) with videos related to

Pageof 22
Sort By:
Acta Neuropathologica|March 9, 2019
cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF<sup>V600E</sup> mutationDavid W Ellison, Cynthia Hawkins, David T W Jones, et al.
Journal of Neuropathology and Experimental Neurology|February 7, 2002
Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma"Hikaru Sasaki, Magdalena C Zlatescu, Rebecca A Betensky, et al.
Journal of Cutaneous Pathology|January 26, 2023
Atretic cephalocele and encephalocele: A single-institution clinicopathological studyMelanie Lang-Orsini, Samantha N Champion, Ann-Christine Duhaime, et al.
Acta Neuropathologica|July 10, 2007
The 2007 WHO classification of tumours of the central nervous systemDavid N Louis, Hiroko Ohgaki, Otmar D Wiestler, et al.
Neuro-Oncology|October 11, 2017
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendationsJohn C DeWitt, Justin T Jordan, Matthew P Frosch, et al.
Pain|July 12, 2003
Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheresDaniel S Kohane, Sarah E Smith, David N Louis, et al.
Journal of Neuropathology and Experimental Neurology|December 6, 2006
Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2Audrey Rousseau, Catherine L Nutt, Rebecca A Betensky, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2014
Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of ciliaRobert T Jones, Malak S Abedalthagafi, Mohan Brahmandam, et al.
Journal of the National Cancer Institute|December 17, 2011
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cellsRyuichi Kanai, Samuel D Rabkin, Stephen Yip, et al.
Journal of Neuro-Oncology|July 16, 2016
Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying)Quinn T Ostrom, Haley Gittleman, Carol Kruchko, et al.
Pageof 22

Showing results (91-100 of 218) with videos related to

Sort By:
Pageof 22
Acta Neuropathologica|March 9, 2019
cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF<sup>V600E</sup> mutationDavid W Ellison, Cynthia Hawkins, David T W Jones, et al.
Journal of Neuropathology and Experimental Neurology|February 7, 2002
Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma"Hikaru Sasaki, Magdalena C Zlatescu, Rebecca A Betensky, et al.
Journal of Cutaneous Pathology|January 26, 2023
Atretic cephalocele and encephalocele: A single-institution clinicopathological studyMelanie Lang-Orsini, Samantha N Champion, Ann-Christine Duhaime, et al.
Acta Neuropathologica|July 10, 2007
The 2007 WHO classification of tumours of the central nervous systemDavid N Louis, Hiroko Ohgaki, Otmar D Wiestler, et al.
Neuro-Oncology|October 11, 2017
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendationsJohn C DeWitt, Justin T Jordan, Matthew P Frosch, et al.
Pain|July 12, 2003
Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheresDaniel S Kohane, Sarah E Smith, David N Louis, et al.
Journal of Neuropathology and Experimental Neurology|December 6, 2006
Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2Audrey Rousseau, Catherine L Nutt, Rebecca A Betensky, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2014
Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of ciliaRobert T Jones, Malak S Abedalthagafi, Mohan Brahmandam, et al.
Journal of the National Cancer Institute|December 17, 2011
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cellsRyuichi Kanai, Samuel D Rabkin, Stephen Yip, et al.
Journal of Neuro-Oncology|July 16, 2016
Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying)Quinn T Ostrom, Haley Gittleman, Carol Kruchko, et al.
Pageof 22